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Abstract
Background: Micafungin is a well-tolerated and effective prophylactic antifungal agent used in hematologic
diseases. In this prospective trial, we evaluated the efficacy and safety of prophylactic micafungin during first
induction chemotherapy in patients with acute leukemia. We also compared outcomes of prophylactic micafungin
with those of prophylactic posaconazole in acute myeloid leukemia (AML).
Methods: Medically fit patients with newly diagnosed acute leukemia received 50 mg micafungin intravenously
once daily from the initiation of first induction chemotherapy to recovery of neutrophil count, suspected fungal
infection, or unacceptable drug-related toxicity (Clinicaltrials.gov number, NCT02440178). The primary end point was
incidence of invasive fungal infection, and the secondary end points were adverse events of prophylactic
micafungin and mortality during induction therapy.
Results: The 65 patients (median age = 51 years, male:female = 34:31) enrolled in this study had diagnoses of AML
(33, 50.8%), acute lymphoblastic leukemia (31, 47.7%), and acute biphenotypic leukemia (1, 1.5%). Median duration
of micafungin treatment was 24 days (range 1–68), with proven invasive fungal disease in one patient (1.5%) and
possible fungal infection in two patients (3.1%). Three of the patients (4.6%) experienced the following adverse
events, but all events were tolerable: liver function abnormality (Grade 2, n = 1; Grade 3, n = 1) and allergic reaction
(Grade 2, n = 1). Three patients died during induction therapy, and invasive aspergillosis pneumonia was the cause
of death for one of those patients. Overall, 19 patients (29.2%) discontinued prophylactic micafungin, and 18 (27.7%)
patients switched to another antifungal agent. We observed no fungal infections caused by amphotericin B-resistant
organisms. In AML patients, outcomes of prophylactic micafungin during induction chemotherapy did not differ
significantly with those of prophylactic posaconazole with regard to incidence of fungal infections, rate of
discontinuation, or safety.
Conclusions: Our study demonstrates that prophylactic micafungin is safe and effective in patients with acute
leukemia undergoing induction chemotherapy. Outcomes in patients with AML were similar to those of prophylactic
posaconazole, indicating the usefulness of micafungin as a prophylactic antifungal agent during induction
chemotherapy for AML.
Trial registration: Clinicaltrials.gov NCT02440178, registered May 12th 2015.
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Background
Over the past decades, treatment-related mortality (TRM)
rates during induction chemotherapy in patients with
acute leukemia have decreased because of improved
supportive care [1]. However, according to reports by
the SWOG cancer research network and MD Anderson
Cancer Center, TRM within 28 days after initiation of
induction chemotherapy remains at approximately 3–
4% [2]. Infection is the major cause of TRM and patient
transfer to the intensive care unit during this period
[3]. In particular, invasive fungal infections are common
causes of morbidity and mortality in patients with acute
leukemia. The estimated incidence of proven/probable
invasive fungal disease after diagnosis is 11.1% at 100
days [4, 5]. A prospective, observational study of pa-
tients with acute myeloid leukemia (AML) reported
that the incidence rate of fungal infection during induc-
tion therapy was approximately 34.6%, and presence of
an invasive fungal infection during induction independ-
ently predicted worse survival [6]. Strategies to address
this problem include diagnostic laboratory tests, com-
puted tomography scan for early detection, and early
treatment [7].
Earlier work in this area has demonstrated the use-
fulness of prophylactic antifungal agents in patients
with acute leukemia, with the choice of antifungal
agent used based on type of leukemia, patient charac-
teristics, and type of treatment [8]. Most patients with
acute leukemia undergoing induction chemotherapy
or hematopoietic stem cell transplantation (HSCT)
are classified as high risk, with aspergillosis species as
one of the key pathogens [8]. Prophylactic fluconazole
decreases the rate of fungal infections during induc-
tion chemotherapy compared to placebo [9] but has
no activity against aspergillosis species and certain
strains of Candida, including C. krusei and C. glab-
rata [10]. More recently, the use of anti-mold agents,
such as posaconazole and echinocandins has been
shown to decrease mortality in patients with acute
leukemia at high risk for invasive fungal infections.
The European Conference on Infections in Leukemia
guidelines recommend posaconazole prophylaxis dur-
ing induction therapy in acute leukemia [4, 11]; how-
ever, the use of posaconazole is limited because its
absorption is influenced by genetic polymorphisms,
gastrointestinal pH, and diet [12–15].
Micafungin, which is the only echinocandin used as a
prophylactic antifungal agent in hematological diseases,
has demonstrated good efficacy and tolerable safety in pa-
tients undergoing HSCT [16–19]. However, data are lim-
ited on the prophylactic use of micafungin during
induction chemotherapy in acute leukemia [20–22].
Therefore, this prospective trial evaluated the efficacy
and safety of micafungin as a prophylactic antifungal
agent for patients with acute leukemia during induction
chemotherapy. Additionally, we compared these efficacy
and safety outcomes with those of prophylactic posaco-
nazole, which was previously evaluated in an observa-




In this prospective, single-arm, open-label study
(Clinicaltrials.gov number, NCT02440178), we enrolled
patients with newly diagnosed acute leukemia (AML,
acute lymphoblastic leukemia [ALL], and acute biphenoty-
pic leukemia [ABL]) who received intensive induction
chemotherapy at Seoul National University Hospital
(SNUH) and Seoul National University Bundang Hospital
from September 2015 through June 2017. All patients en-
rolled in the study provided written informed consent. In-
clusion criteria were as follows: 1) ≥ 18 years old; 2) Acute
leukemia diagnosed by bone marrow examination; 3) in-
tensive induction chemotherapy; 4) Eastern Cooperative
Oncology Group performance status score ≤ 2; and 5)
serum creatinine and bilirubin levels < 1.5 times the upper
limit of the reference range for our laboratory. Exclusion
criteria were as follows: 1) suspected fungal infection 30
days before initiation of induction chemotherapy; 2) his-
tory of hypersensitivity to echinocandin; 3) diagnosis of
other malignancy in the previous 5 years; 4) previous
chemotherapy, radiation, or immunosuppressive treat-
ment; 5) immunodeficiency disease; 6) pregnant or breast-
feeding; 7) uncontrolled seizures or mental illness; 8)
acute myocardial infarction, uncontrolled arrhythmia, or
low ejection fractions (< 40%); 9) previous organ trans-
plantation; and 10) interstitial lung disease.
Patients received 50 mg micafungin intravenously
once daily from the initiation of induction chemotherapy
to recovery of neutrophil count (absolute neutrophil count
> 500/μg for three consecutive days), suspected fungal
infection, or occurrence of drug-related toxicity. The
primary end point was incidence of invasive fungal
infection, and the secondary end points were adverse
events of prophylactic micafungin and mortality dur-
ing induction chemotherapy. The study flow diagram
is shown in Fig. 1. Patients were followed up for 6
and 12 weeks after the initiation of induction chemo-
therapy for the occurrence of fungal infection and
survival, respectively.
The determination of sample size
The previous study showed that the incidence of fungal
infections was about 29.2% in prophylactic fluconazole
group and 13.8% in posaconazole group [24]. We hypoth-
esized that the incidence of fungal infections in the
prophylactic micafungin group was reduced by 15.4%
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(assuming that the incidence is similar to that of the
prophylactic posaconazole group) from that of prophylac-
tic fluconazole group. Therefore, a sample size of 65 pa-
tients was required for this study based on a statistical
power of 80% and a significance level of 5%, including a
dropout rate of 10%.
Diagnosis of invasive fungal infection
For all patients, baseline chest x-rays were obtained
within 7 days after the initiation of induction chemo-
therapy. Aspergillus infection was diagnosed according
to the criteria for invasive pulmonary aspergillosis of
the European Organization for Research and Treatment
of Cancer/Invasive Fungal Infections Cooperative
Group and the National Institute of Allergy and Infec-
tious Diseases Mycoses Study Group (EORTC/MSG)
Consensus Group [25]. An invasive fungal infection
was defined as “proven” by a positive culture for fungus
with symptoms and signs of a fungal infection, as
“probable” by direct or indirect detection (galactoman-
nan antigen or serum β–D-glucan) with clinical and
radiographic findings, or as “possible” if sufficient clin-
ical evidence for fungal infection was present without
mycological evidence.
Fig. 1 The consort diagram of study
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Comparison of outcomes of prophylactic micafungin with
those of previously performed prophylactic posaconazole
trial
We compared the efficacy and safety of prophylactic
micafungin with those of prophylactic posaconazole
during induction chemotherapy in AML patients
treated at SNUH [23]. This prospective observational
trial compared plasma posaconazole concentrations in
patients who received posaconazole as an oral suspen-
sion versus tablet. From September 2014 to April
2017, we enrolled patients who received prophylactic
posaconazole while undergoing induction chemother-
apy for AML or myelodysplastic syndrome. Among
these patients, we selected patients with AML who
met the inclusion criteria of our study for comparison
with patients who received prophylactic micafungin in
the present study.
Statistical analysis
Categorical variables were compared using Pearson’s
chi-square test or Fisher’s exact test, as appropriate. Cu-
mulative incidence of fungal infection and the time from
initiation of micafungin treatment to a switch to another
antifungal agent were evaluated by Kaplan–Meier ana-
lysis. All analyses were performed using SPSS for Win-
dows, version 23.0 (IBM; Armonk, NY, USA); All
statistical tests were two-sided, and significance was de-
fined as P < 0.05.
Ethical considerations
This study was approved by the institutional review
board at Seoul National University Hospital (IRB;
H-1412-022-631) and was conducted in accordance with
the guidelines of the Declaration of Helsinki for biomed-




Sixty-five patients were enrolled in this study (Table 1).
Median patient age was 51 years (range, 18–84 years).
Diagnoses were AML (n = 33, 50.8%), ALL (31, 47.7%),
and ABL (n = 1, 1.5%). All patients received intensive in-
duction chemotherapy.
Efficacy and adverse events of micafungin prophylaxis
The median duration of micafungin treatment was 24 days
(range 1–68 days) (Table 1). During induction chemother-
apy, invasive fungal infection was detected in three of the
65 patients (4.6%), with proven invasive fungal disease in
one patient (1.5%) and possible fungal infection in two pa-
tients (3.1%) (Table 2 and Fig. 2). The patient with proven
invasive fungal disease had an initial diagnosis of poor-risk
AML (transformation of myelodysplastic syndrome to
AML) and received cytarabine and idarubicin induction
chemotherapy. During treatment, the patient developed
uncontrolled fever, and invasive pulmonary aspergillosis
was diagnosed by bronchoscopic biopsy on day 25 after
Table 1 Baseline patient characteristics
Patient characteristics Patients (n = 65)
Median age, years (range) 51 (18–84)
Age group, n (%)
< 60 years 48 (73.8)






De novo AML 23 (35.4)















Induction chemotherapy, n (%)
AID-based regimen 30 (46.2)
Modified FLAI 3 (4.6)
VPD-based regimen 30 (46.2)
ADVP-based regimen 2 (3.1)
Median BM blast percentage at diagnosis
(range)
80.0 (12.9–98.5)
Median duration of micafungin treatment,
days (range)
24 (1–68)
Median time from induction chemotherapy
to severe neutropenia (ANC < 500/μL), days (range)
24 (11–84)
Abbreviations: AML Acute myeloid leukemia, ALL Acute lymphoblastic
leukemia, ABL Acute biphenotypic leukemia, AID Cytarabine + idarubicin, FLAI
Fludarabine + cytarabine + idarubicin, VPD Vincristine + prednisolone +
daunorubicin, ADVP Cytarabine + daunorubicin + vincristine + prednisolone,
BM Bone marrow, ANC Absolute neutrophil count; aSecondary AML (10)
included AML transformation from myelodysplastic syndrome (8), AML
transformation from chronic myelomonocytic leukemia (1) and treatment-
related AML (1)
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initiation of induction chemotherapy. Although she
was treated with voriconazole, the fungal pneumonia
gradually worsened, and diffuse alveolar hemorrhage
developed. This patient died in intensive care unit
due to pneumonia septic shock and aggravated diffuse
alveolar hemorrhage. One patient with possible fungal
infection had a diagnosis of poor-risk AML and was
treated with cytarabine and idarubicin induction
chemotherapy. She experienced erythematous nodular
skin lesions and pneumonia, and fungal infection was
suspected on day 23 after initiation of chemotherapy.
After treatment with liposomal amphotericin B, the
skin lesions and pneumonia improved. The other pa-
tient with possible fungal infection had a diagnosis of
Philadelphia-positive ALL and received vincristine,
prednisolone, daunorubicin, L-asparaginase, and ima-
tinib (VPDL + imatinib) chemotherapy. Fungal pneu-
monia was suspected based on computed tomography
imaging on day 9 after initiation of chemotherapy.
The pneumonia was treated with voriconazole and
gradually improved.
Nineteen of the 65 patients (29.2%) discontinued prophy-
lactic micafungin because of prolonged neutropenic fever
(n = 14, 21.5%), fungal infection (n = 3, 4.6%), or adverse
events (n = 2, 3.1%) (Table 2). Of these 19 patients, 18 pa-
tients changed to other antifungal agents; 1 patient changed
to itraconazole; 1 patient changed to posaconazole, 2 pa-
tients changed to voriconazole, and 14 patients changed to
liposomal amphotericin B. The reasons for the change to
other antifungal agents were as follows: 3 patients were sus-
pected of having fungal infections; 14 patients experienced
prolonged neutropenic fever, and 1 patient developed a
grade 2 allergic reaction. The time from initiation of mica-
fungin to a switch to another antifungal agent was 46 days
(95% confidence interval [CI], 27–64 days) (Fig. 3).
Three of the 65 patients (4.6%) experienced the follow-
ing micafungin-related adverse events: Grade 2 or 3 liver
function abnormality (n = 2, 3.1%) and Grade 2 allergic
reaction (n = 1). Micafungin treatment was interrupted
for the patient with Grade 3 liver function abnormality,
and liver enzyme levels gradually improved, returning to
the reference range after 22 days. The patient with Grade
2 liver function abnormality continued on prophylactic
micafungin, and liver enzyme levels returned to the
Table 2 Discontinuation and adverse events of prophylactic
micafungin during first induction chemotherapy
Number of
patients (%)
Incidence of fungal infection 3/65 (4.6)
Proven fungal infection 1/65 (1.5)
Probable fungal infection 0
Possible fungal infection 2/65 (3.1)
Discontinuation of prophylactic micafungin 19/65 (29.2)
Cause of discontinuation
Suspected fungal infections 3/65 (4.6)
Prolonged neutropenic fever 14/65 (21.5)
Adverse events 2/65 (3.1)
Micafungin treatment completed 46/65 (70.8)
Switch to another antifungal agent 18/65 (27.7)
Adverse events related to micafungin 3/65 (4.6)
Liver function test abnormality 2/65 (3.1)
Grade 2 1/65 (1.5)
Grade 3 1/65 (1.5)
Allergic reaction 1/65 (1.5)
Grade 2 1/65 (1.5)
No adverse event 62/65 (95.4)
Cause of mortality during induction chemotherapy 3/65 (4.6)
Fungal infection (proven) 1/65 (1.5)
Respiratory failure (pneumonia and pulmonary edema) 1/65 (1.5)
Septic shock 1/65 (1.5)
Fig. 2 Kaplan–Meier curve of cumulative incidence of fungal
infection during induction chemotherapy
Fig. 3 Kaplan–Meier curve showing time from initiation of
prophylactic micafungin to switch to another antifungal agent
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reference range. The patient with the allergic reaction
(sudden chest discomfort, dizziness, abdominal pain,
and drop in systolic blood pressure from 140mmHg to
93mmHg) recovered after discontinuation of micafungin
and treatment with an antihistamine.
In three patients, chemotherapy-related death oc-
curred due to invasive aspergillosis pneumonia (n = 1,
on day 39), septic shock (n = 1, on day 45), or respiratory
failure caused by pulmonary edema and pneumonia (n = 1,
on day 30). No patients experienced fungal infections
caused by amphotericin B-resistant organisms after induc-
tion chemotherapy.
Comparison of micafungin prophylaxis with posaconazole
prophylaxis in patients with newly diagnosed AML
receiving induction chemotherapy
A subgroup analysis of AML patients in our study (n = 32)
showed that two patients (6.3%) experienced invasive fun-
gal infections (proven infection, n = 1; possible infection,
n = 1). Seventeen of the patients (53.1%) discontinued
prophylactic antifungal treatment, and 16 (50.0%)
switched to another antifungal agent. A comparison with
AML patients who received posaconazole at SNUH in a
previous study [23] showed no significant differences in
baseline characteristics except for bone marrow blast
percentage at diagnosis (P = 0.02) (Table 3). No sig-
nificant differences between the two groups were
found regarding incidence of total invasive fungal in-
fections (1 proven and one possible fungal infection
in the micafungin group vs. 2 probable fungal infec-
tions in the posaconazole group; P = 1.000); discon-
tinuation of the prophylactic agent (17/32 [53.1%] for
the micafungin group vs. 20/39 [51.3%] for the
posaconazole group; P = 0.877); or switch to another
antifungal agent (16/32 [50.0%] for the micafungin
group vs. 20/39 [51.3%] for the posaconazole group;
P = 0.914) (Table 4). Additionally, the incidence of ad-
verse events did not differ significantly between
groups (2/32 patients [6.3%] in the micafungin group
vs. 4/39 patients [10.3%] in the posaconazole group;
P = 0.683). All adverse events in the posaconazole
group were liver function abnormalities. Finally, no
significant differences between the two groups were
found regarding mortality during induction chemotherapy
(3/32 patients [9.4%] in the micafungin group vs. 2/39 pa-
tients [5.1%] in the posaconazole group; P = 0.652) or time
from the initiation of micafungin to switch to another an-
tifungal agent (33 days for the micafungin group vs. 37
days for the posaconazole group; P = 0.900) (Fig. 4).
Discussion
Despite improvement in supportive care, invasive fungal
infections remain among the most common causes of
mortality in patients with high risk hematologic diseases;
therefore, prophylactic antifungal treatment is used in
these patients [8]. In acute leukemia, induction chemo-
therapy is a period in which patients are particularly
vulnerable to fungal infections [8]. Considering drug
toxicity, coverage of pathogens, and safety, current
guidelines strongly recommend the use of prophylactic
posaconazole during induction chemotherapy (Grade 1A
recommendation) [11].
Previous clinical trials have demonstrated the efficacy and
safety of prophylactic micafungin for hematologic malig-
nancies. For example, Van Burik, et al. reported that the
overall efficacy of micafungin was superior to that of







Median age, years (range) 57 (21–84) 52 (18–73) 0.408
Sex, n (%)
Male 18 (56.3) 19 (48.7)
Female 14 (43.8) 20 (51.3) 0.527
Disease, n (%)
De novo AML 23 (71.9) 33 (84.6) 0.191
Secondary AML 9 (28.1) 6 (15.4)
Induction chemotherapy, n (%)
AID-based regimen 29 (90.6) 32 (82.1) 0.495
Modified FLAI 3 (9.4) 7 (17.9)
Median BM blast percentage at diagnosis (range) 62.6 (12.9–95.4) 32.2 (17.7–99.0) 0.020
Median duration of micafungin treatment, days (range) 26.0 (1.0–68.0) 25.0 (7.0–95.0) 0.782
Median time from chemotherapy to severe neutropenia, days (range) 28.5 (11.0–84.0) 28.0 (7.0–139.0) 0.776
Abbreviations: AML Acute myeloid leukemia, AID Cytarabine + idarubicin, FLAI Fludarabine + cytarabine + idarubicin, BM Bone marrow
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fluconazole after HSCT (treatment success rate: 80% for
micafungin vs. 73.5% for fluconazole; P = 0.03) [19]. A pre-
vious Korean study reported superior cost-effective out-
comes with prophylactic micafungin compared with
prophylactic fluconazole during HSCT (total cost differ-
ence: 95,511,000 Korean Won per 100 patients) [26]. In
addition, a multicenter, randomized, phase III trial also
found that micafungin was as effective as itraconazole in
the prevention of invasive fungal infections in patients
undergoing HSCT (treatment success rate: 92.6% for
micafungin vs. 94.6% for itraconazole; P = 0.48) and was
also better tolerated (drug-related adverse events: 11% for
micafungin vs. 39% for itraconazole; P < 0.001) [27]. Finally,
a meta-analysis of randomized controlled trials showed sig-
nificantly higher success rates for micafungin compared
with triazole (fluconazole, voriconazole and itraconazole) in
patients undergoing intensive chemotherapy or HSCT
(relative risk [RR] = 1.15) and fewer severe adverse events
(RR = 0.45; P = 0.0105) [28].
The results of our study indicate that micafungin may
be a useful prophylactic antifungal agent in patients with
acute leukemia during induction chemotherapy. In pa-
tients with AML, prophylactic micafungin was not inferior
to posaconazole with regard to efficacy or safety. In
addition, the adverse events of micafungin were tolerable.
Moreover, micafungin has several advantages as a
prophylactic antifungal agent. Because it is administered
intravenously, micafungin is useful for patients undergo-
ing intensive chemotherapy, which causes side effects
that interfere with oral intake (e.g., severe oral mucositis
or nausea/vomiting). Micafungin also has a low rate of
drug-drug interactions compared with posaconazole,
which inhibits cytochrome P450 enzymes [15, 29] and
could therefore interact with drugs such as histamine
H2 receptor antagonists, proton pump inhibitors, and
calcium channel blockers. Especially, micafungin could
Table 4 Outcomes of prophylactic micafungin vs. posaconazole during first induction chemotherapy in newly diagnosed AML
patients
Micafungin, n (%) Posaconazole, n (%) P-value
Incidence of fungal infection 2/32 (6.3) 2/39 (5.1) 1.000
Proven fungal infection 1/32 (3.1) 0
Probable fungal infection 0 2/39 (5.1)
Possible fungal infection 1/32 (3.1) 0
Discontinuation of prophylactic antifungal agent 17/32 (53.1) 20/39 (51.3) 0.877
Cause of discontinuation
Suspected fungal infection 2/32 (6.3) 2/39 (5.1)
Prolonged neutropenic fever 13/32 (40.6) 17/39 (43.6)
Any adverse event 2/32 (6.3) 0
Oral mucositis 0 1/39 (2.6)
Antifungal treatment completed 15/32 (46.9) 19/39 (48.7)
Change to another antifungal agent 16/32 (50.0) 20/39 (51.3) 0.914
Adverse event of prophylactic antifungal agent 2/32 (6.3) 4/39 (10.3) 0.683
Liver function test abnormality 1/32 (3.1) 4/39 (10.3)
Allergic reaction (Grade 2) 1/32 (3.1) 0
No adverse event 30/32 (93.8) 35/39 (89.7)
Cause of mortality during chemotherapy 3/32 (9.4) 2/39 (5.1) 0.652
Fungal infection (proven) 1/32 (3.1) 0
Respiratory failure (pneumonia, pulmonary edema) 1/32 (3.1) 1/39 (2.6)
Septic shock 1/32 (3.1) 1/39 (2.6)
Fig. 4 Kaplan–Meier curve showing time from initiation of
prophylactic micafungin or posaconazole to a switch to another
antifungal agent
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overcome the severe neurotoxicity which could increase
through interaction between antifungal azole and vin-
cristine (one of the important drug in ALL) [30]. Fur-
thermore, plasma levels of posaconazole must be
monitored to determine bioavailability, which is affected
by diet, mucositis, genetic polymorphisms, gastrointes-
tinal pH, as well as other drugs [12–15]. In contrast,
micafungin has a wide safety range, and plasma levels of
micafungin do not correlate with degree of hepatic or
renal dysfunction [31].
Micafungin use is limited by its lack of activity against cer-
tain species of fungus including Cryptococcus, Coccidioides,
Zygomycetes, and Scedosporium species [32]. Although the
rates of fusariosis and zygomycosis infections have recently
increased because of the extensive use of antifungal prophy-
laxis, most fungal infections in acute leukemia patients are
still caused by Aspergillus species (55–58%) and Candida
species (26–40%) [32–34], which can be successfully treated
with micafungin. In addition, safety is also an important con-
cern when selecting a prophylactic antifungal agent. For ex-
ample, a prospective, randomized study comparing
fluconazole with the broad-spectrum antifungal agent
amphotericin B for antifungal prophylaxis found an in-
creased risk of nephrotoxicity amphotericin B but no in-
crease in efficacy [35]. Therefore, not only the efficacy but
also the safety should be considered when selecting a
prophylactic antifungal agent.
Limitations of our study include its small sample size
and the single-arm study design. The observational study
of posaconazole used for comparison also had a small
sample size; therefore, large-scale studies are needed to
confirm our results. Nevertheless, we believe this study
could be helpful for the selection of antifungal agents in
patient with acute leukemia treated with first-line induc-
tion chemotherapy.
Conclusions
In conclusion, our study demonstrates that prophylactic
micafungin is safe and effective in patients with acute
leukemia undergoing induction chemotherapy. In pa-
tients with AML, the effectiveness and tolerability of
micafungin is similar to those of posaconazole.
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